Catenin Beta 1 Pipeline Review, H2 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Catenin Beta 1 - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

The latest report Catenin Beta 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or 1-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes.

It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Key Topics Covered:

Introduction

Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development

• Aileron Therapeutics Inc
• Circle Pharma Inc
• Dicerna Pharmaceuticals Inc
• Fog Pharmaceuticals Inc
• iBeCa Therapeutics
• MD2 Biosciences Inc
• PRISM Pharma Co Ltd
• Propanc Biopharma Inc
• Sapience Therapeutics Inc
• Sumitomo Dainippon Pharma Oncology, Inc
• Venn Therapeutics LLC
• WntRx Pharmaceuticals Inc

Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

BBI-801 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

exisulind - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Oligonucleotides for Hepatoblastoma - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

PRI-724 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

PRP - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Small Molecule to Inhibit Beta Catenin for Colorectal Cancer - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Synthetic Peptide for Oncology - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

WX-024 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress
• Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones

• Featured News & Press Releases
• Jun 17, 2020: Sapience Therapeutics to present data on ?-catenin antagonist program at 2020 AACR Virtual Annual Meeting II
• Apr 14, 2020: Propanc Biopharma receives first allowance for key patent family from Australian Patent Office
• Jan 21, 2020: Propanc Biopharma receives advance overseas finding from Innovation and Science Australia
• Oct 21, 2019: Propanc Biopharma illustrates novel mode of action of PRP, suppressing EMT Pathways and Metastasis in Cancer Patients
• Aug 21, 2019: Propanc Biopharma receives granted US patent covering additional composition claims for PRP
• Aug 12, 2019: Propanc Biopharma publishes key data in peer reviewed journal confirming anti-cancer stem cell effects of Proenzymes
• Aug 08, 2019: Propanc Biopharma completes development of bio-analytical assay method to quantify PRP active ingredients in preparation for first-in-human study
• Jul 15, 2019: Propanc Biopharma provides update on preparation of PRP for clinical trial application submission and recently completed reverse stock split
• Jun 27, 2019: Propanc Biopharmas Intellectual Property portfolio undergoes rapid growth
• May 06, 2019: Propanc Biopharma appoints Dr. Ralf Brandt to its scientific advisory board
• Apr 26, 2019: Announcement of the signing of a joint R & D agreement and commencement of development activities regarding "Research and development of innovative antifibrotic drugs to improve the life prognosis of cirrhosis"
• Mar 25, 2019: Propanc Biopharma initiates development of bio-analytical assay in preparation for human trials
• Mar 13, 2019: Propanc Biopharma receives notice of allowance for additional claims from foundation patent in the U.S.
• Dec 20, 2018: Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline
• Nov 14, 2018: Adoption as a practical realization development type of the cyclic innovation for clinical empowerment by the Japan Agency for Medical Research and Development

Appendix

Companies Mentioned

• Aileron Therapeutics Inc
• Circle Pharma Inc
• Dicerna Pharmaceuticals Inc
• Fog Pharmaceuticals Inc
• iBeCa Therapeutics
• MD2 Biosciences Inc
• PRISM Pharma Co Ltd
• Propanc Biopharma Inc
• Sapience Therapeutics Inc
• Sumitomo Dainippon Pharma Oncology, Inc
• Venn Therapeutics LLC
• WntRx Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o5hfvo